The U.S. Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi). The drug, a monoclonal antibody, binds to amyloid beta in the brain. An 18-month study published in the New England Journal of Medicine1 found Leqembi reduced markers of amyloid in early Alzheimer’s disease and led to “moderately less decline”… Read More »
FDA Grants Accelerated Approval for Aduhelm (aducanumab-avwa) for the Treatment of Alzheimer’s Disease CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Aduhelm™ (aducanumab-avwa) as the first and only Alzheimer’s… Read More »
Every company is a tech company, strategy consultants asserted over the past decade. The coronavirus pandemic has revealed that every company is a health and wellness company now, at least in the eyes of consumers around the world. In The Wellness Gap, the health and wellness team at Ogilvy explores the mindsets of consumers in… Read More »